No Data
BASECARE-B (02170): Zhao has been nominated as a non-executive Director.
BASECARE-B (02170) announces that the Board of Directors has reviewed and approved the re-election of Jiang Junchao for...
Industry Partnership | Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement
Suzhou Basecare Enters Assisted Reproduction Cooperation Contract
BASECARE-B (02170.HK) has signed a Global Strategy cooperation agreement with Qinghua Medical.
On December 24, Glonghui reported that BASECARE-B (02170.HK) announced that the group has signed a Global Strategy cooperation agreement with Shanghai Jinghua Medical Management Co., Ltd. ("Jinghua Medical") on December 24, 2024. This cooperation agreement will be effective from the date of signing and will last for five years. Under the Global Strategy cooperation agreement, the group will provide Jinghua Medical with AI-based one-stop multi-scenario solutions covering areas such as urological testing, embryo culture, refrigerated storage, and complex genetic disease diagnosis and treatment, aiming to create an internationally leading benchmark center for Assisted Reproduction. The scope of cooperation under the Global Strategy agreement includes: (i) Jinghua
Express News | Suzhou Basecare Medical - Strategic Cooperation Agreement With Jinghua Medical
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
No Data
